VJHemOnc is committed to improving our service to you

ASH 2019 | ddPCR for rapid screening of actionable KD mutations in CML

VJHemOnc is committed to improving our service to you

Hugues de Lavallade

Hugues de Lavallade, MD, PhD, King’s College London, London, UK, outlines a novel droplet digital PCR-based (ddPCR) multiplex assay for rapid screening for a panel of BCR-ABL1 kinase domains mutations relevant for tyrosine kinase inhibitors (TKIs). Dr Lavallade discusses the pros and cons of the use of ddPCR in this setting, including the potential clinical benefits. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter